Table 5.
Summary of previous studies for the investigation of the efficacy of third-line eradication therapy for H. pylori infection.
First author [ref. no.]s | Year | Method | VPZ-containing eradication regimen |
PPI-containing eradication regimen |
|||||
---|---|---|---|---|---|---|---|---|---|
Number | Regimen | Eradication rate | Number | Regimen | Eradication rate | ||||
Sugimoto (Sugimoto et al., 2017) | 2017 | OS | ITT | 15 | VPZ: 20 mg bid AMX: 500 mg qid STFX: 100 mg bid |
80.0% | |||
Sue (Sue et al., 2018b) | 2018 | RCT | ITT | 33 | VPZ: 20 mg bid AMX: 750 mg bid STFX: 100 mg bid |
75.8% | 30 | LPZ: 30 mg bid, RPZ: 10 mg bid or EPZ: 20 mg bid AMX: 750 mg bid STFX: 100 mg bid |
53.3% |
All paper to investigate efficacy of third-line vonoprazan-containing eradication therapy up until September 2018 were listed. AMX, amoxicillin; bid, twice daily dosing; EPZ, esomeprazole; ITT, intention to treat analysis; LPZ, lansoprazole; MNZ, metronidazole; PPI, proton pump inhibitor; OS, observational study; qid, four times daily dosing; RCT, randomized control trial; RST, retrospective cohort trial; RPZ, rabeprazole; STFX, sitafloxacin; VPZ, vonoprazan.